BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

ASRT: Generic Risk Extends Timeline, PT $6

ASRT: ASEG Guideline a Significant Positive, PT to $8

ASRT: Updated Q4 Results Puts 2023 in Focus

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul>
<li>ASRT is purchasing Spectrum Pharmaceuticals (SPPI) in an all-stock transaction that adds ROLVEDON to its product portfolio.</li>
<li>The initial reaction to the deal has been materially negative after ASRT added it would maintain a majority of SPPI's operating expenses.</li>
<li>ASRT's management has been looking for an asset that would help diversify the revenue stream away from Indocin. The purchase of SPPI achieves such a goal</li>
</ul>


ASRT is purchasing Spectrum Pharmaceuticals (SPPI) in an all-stock transaction that adds ROLVEDON to its product portfolio.
The initial reaction to the deal has been materially negative after ASRT added it would maintain a majority of SPPI's operating expenses.
ASRT's management has been looking for an asset that would help diversify the revenue stream away from Indocin. The purchase of SPPI achieves such a goal


Assertio Holdings

ASRT: Rolling with Spectrum